post myocardial infarction clinical trials results

any anticoagulant versus aspirin
EPSIM, 1982	anticoagulant versus aspirin 500mg three times daily	patients surviving myocardial infarction	open Follow-up duration: 29 months (range 6-59)
any anticoagulant versus placebo
Sixty Plus reinfarction Study, 1980	anticoagulant versus placebo	over 60 years of age	double blind Follow-up duration: 2 years
aspirin versus placebo
CDPA, 1976	Aspirin (324 mg) 3x/d versus Placebo	MI survivors	Double blind Follow-up duration: 1.83 y USA
Cardiff I, 1974	Aspirin (300 mg) 1x/d versus Placebo	MI survivors	Double blind Follow-up duration: 2 years UK
Cardiff II, 1979	Aspirin (300 mg) 3x/d for one year versus Placebo	patients with myocardial infarction	Double blind Follow-up duration: 1 y South Wales
Vogel, 1979	Aspirin (1.5 g daily) on an average period of 22 months versus Placebo		Double blind Follow-up duration: 1.75 y (mean) Germany
AMIS, 1980 NCT00000491	Aspirin (500 mg) 2x/d for at least 3 years versus Placebo	men and women who had had a documented myocardial infarction	Double blind Follow-up duration: > 3 y USA
GAMIS, 1980	Aspirin (500 mg) 3x/d for 2 years versus Placebo	patients who had survived a myocardial infarction for 30-42 days	Double blind Follow-up duration: 2 y Germany, Austria,
PARIS, 1980	Aspirin (324 mg) 3x/d versus Placebo	patients who had recovered from myocardial infarction	Double blind Follow-up duration: 41 mo USA, UK
JAMIS, 1999	Aspirin (81 mg) 1x/d versus No antiplatelets	patients with AMI within 1 month from the onset of symptoms	Open Follow-up duration: 1.3 y (mean) Japan
atorvastatin high dose versus atorvastatin
TNT, 2005 NCT00327691	80 mg of atorvastatin daily versus 10 mg of atorvastatin daily	Chronic coronary artery disease LDL cholesterol < 3.4 mmol/L	double blind Follow-up duration: 4.9 years 14 countries
atorvastatin high dose versus lovastatin
Vascular basis, 2005	atorvastatin (80 mg) with or without vitamin C and E versus low dose lovastatin (5 mg)	Chronic coronary artery disease	double blind Follow-up duration: 1 year
atorvastatin high dose versus pravastatin
REVERSAL, 2004	atorvastatin 80 mg daily versus Pravastatin(40 mg)	Chronic coronary artery disease	double blind Follow-up duration: 1.5 years
SAGE, 2007	atorvastatin 80 mg daily versus pravastatin(40 mg)	Chronic coronary artery disease	double blind Follow-up duration: 1 years
atorvastatin high dose versus simvastatin
IDEAL, 2005 NCT00159835	atorvastatin 80mg daily versus simvastatine 20mg/j	Men and women aged 80 years or younger with a history of a definite myocardial infarction and who qualified for statin therapy according to national guidelines	open Follow-up duration: 4.8 years Denmark, Finland, Iceland, Netherlands, Norway, Sweden
azimilide versus placebo
ALIVE, 2004	azimilide 100 mg versus placebo	post-MI patients with depressed LVF	double blind Follow-up duration: 1y
bezafibrate versus placebo
BECAIT, 1996	bezafibrate 200 mg three times daily versus placebo	dyslipidaemic male survivors of myocardial infarction who were younger than 45 years at the time of the event	double blind Follow-up duration: 5.0 years Sweden
BIP, 2000	bezafibrate 400 mg/d versus placebo	patients with a previous myocardial infarction or stable angina, total cholesterol of 180 to 250 mg/dL, HDL-C < or =45 mg/dL, triglycerides < or =300 mg/dL, and low-density lipoprotein cholesterol < or =180 mg/dL	double blind Follow-up duration: 6.2 y Israel
canakinumab versus placebo
CANTOS, 2017 NCT01327846	Quarterly Subcutaneous Canakinumab 50mg, 150mg, 300mg for 36 months versus placebo	Stable Post-myocardial Infarction Patients With Elevated hsCRP	double-blind Follow-up duration: 36 months
class I drugs versus control
BASIS, 1990	individualized antiarrhythmic treatment versus no antiarrhythmic therapy	patients with persisting asymptomatic complex arrhythmias after myocardial infarction	open Follow-up duration: 1 year
clofibtate+niacin versus placebo
Carlson (Stockholm), 1977	clofibrate, 1 g twice daily, and nicotinic acid 1 g three times daily versus control	survivors of a myocardial infarction below 70 years of age	open Follow-up duration: 5 years Sweden
clopidogrel versus aspirin
CAPRIE, 1996	Clopidogrel (75 mg) 1x/d for a minimum of one year and a maximum of 3 years versus Aspirin (325 mg) 1x/d	patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease	Double blind Follow-up duration: 1.91 y 16 countries (USA, Canada, Europe, Australia and NZ
coumadin versus aspirin
ASPECT-2 (coumadin alone), 2002	coumadin (phenprocoumon or acenocoumarol) target INR 3-4 versus aspirin 80mg daily	Acute MI, unstable angina	open Follow-up duration: 1 year (range 0-26 months) the Netherlands
coumadin versus control (on top of aspirin)
ASPECT-2 (coumadin+ASA vs ASA), 2002	coumadin(INR mean 2.4) +aspirin versus aspirin	Acute MI, unstable angina	open Follow-up duration: 1 year the Netherlands
coumadin versus placebo
ASPECT, 1994	nicoumalone or phenprocoumon, target INR 2.8–4.8 versus placebo	hospital survivors of myocardial infarction	double blind Follow-up duration: 37 months (range 6-76)
d,l sotalol versus placebo
Julian, 1982	sotalol 320 mg once daily versus placebo	surviving an acute myocardial infarction	double blind Follow-up duration: 1 year
dabigatran versus placebo
REDEEM, 2009 NCT00621855	dabigatran 4 dosages (50mg twice daily, 75mg twice daily, 110mg twice daily, 150mg twice daily) versus placebo	patients with recent acute coronary syndromes (ST- or non-ST-elevation myocardical infarction)	double blind Follow-up duration: 6 months
diltiazem versus placebo
MDPIT, 1988	Diltiazem 60mgx4 versus placebo	Patient aged 25 to 75 years, admitted to coronary care units with a documented acute myocardial infarction	Double blind Follow-up duration: 25 months (at least 12 months) US, Canada
dipyridamol + aspirin versus aspirin
PARIS, 1980	Aspirin (324 mg) + dipyridamole (75 mg) 3x/d versus Aspirin (324 mg) 3x/d	patuents who had recovered from myocardial infarction	Double blind Follow-up duration: 41 months USA and GB
dipyridamol + aspirin versus placebo
PARIS, 1980	Aspirin (324 mg) + dipyridamole (75 mg) 3x/d versus Placebo	patients who had recovered from myocardial infarction	Double blind Follow-up duration: 41 months (mean) USA and UK
PARIS-II, 1986	Aspirin (330 mg) + dipyridamole (75 mg) 3x/d versus Placebo	patients who had recovered from myocardial infarction, suffered from 4 weeks to 4 months previously	Double blind Follow-up duration: 23.4 months USA and UK
dofetilide versus placebo
DIAMOND MI, 1997	dofetilide versus placebo	patients with acute myocardial infarction within 7 days and left ventricular systolic dysfunction (EF <= 35%)	double blind Follow-up duration: >12 months Danish
early amiodarone versus control
BASIS, 1990	amiodarone 1 g for 5 d; then 200 mg/d started within 4 weeks of AMI versus no amiodarone (usual care)	patients with persisting asymptomatic complex arrhythmias after myocardial infarction (Lown class 3 or 4b in > 2 of 24 h)	open Follow-up duration: 12 mo
Navarro-Lopez, 1993	amiodarone 600 mg/d for 1 week, 400 mg/d for 1 week then 200 mg/d started 10-30 d after AMI versus no amiodarone	patients who have had MI with a left ventricular ejection fraction of 20 to 45% and > or = 3 ventricular premature complexes per hour (pairs or runs) - 3 VPOs/h, pairs or runs of VT	open Follow-up duration: 24 mo Spain
early amiodarone versus placebo
CAMIAT , 1991	amiodarone 10 mg/kg per d for 3 weeks then 300-400 mg/d started 6-45 d after AMI versus placebo	patients with acute myocardial infarction within the previous 6-30 days and > 10 VPDs/h for 18 h or a run of VT	double blind Follow-up duration: 24 mo
Ceremuzynski, 1992	amiodarone 800 mg/d for 1 week then 200-400 mg/d started 5-7 d after AMI versus placebo	No need for antiarrhythmic therapy	double blind Follow-up duration: 12 mo
Hockings, 1987	amiodarone 200 mg 3 times daily for 1 wk; then 200 mg/d started < 8-10 d after AMI versus placebo	patients with AMI - Absence of VF or VT > 3 beats	double blind Follow-up duration: 6·42 mo
ezetimibe versus placebo (on top statins)
IMPROVE-IT, 2014 NCT00202878	10 mg/day of ezetimibe and 40 mg/day of simvastatin versus simvastatin 40 mg/day	subjects with stabilized high-risk acute coronary syndrome	double blind Follow-up duration: 5.68 years 39 countries
gemfibrozil versus placebo
VA-HIT, 1999 NCT00283335	gemfibrozil 1.2g daily versus placebo	men with coronary heart disease, an HDL cholesterol level of 40 mg per deciliter (1.0 mmol per liter) or less, and an LDL cholesterol level of 140 mg per deciliter (3.6 mmol per liter) or less	double blind Follow-up duration: 5.1 years USA
low fat diet versus mediterranean-style diet
Tuttle, 2008	low-fat versus Mediterranean-style diets	First MI survivors	open Follow-up duration: 24 months
moricizine versus placebo
CAST II (early treatment), 1992	moricizine for 14 days versus placebo	acute myocardial infarction	double blind Follow-up duration: 14 days
CAST II (late treatment), 1992	long term moricizine versus placebo	patient survivor to a myocardial infarctionwhose ventricular premature depolarizations were adequately suppressed by moricizine	double blind
nifedipine versus placebo
SPRINT II, 1993	Nifedipine 20mgx3 started within 3hr of hopsital admission for 6 months versus placebo	men and women with suspected acute MI	Double blind Follow-up duration: 6 months Israel
SPRINT I, 1988	Nifedipine 10mgx3 versus placebo	patient surviving MI 7 and 21 days after admission	Double blind Follow-up duration: 1 year Israel
omega-3 Fatty acids versus control
OMEGA, 2009 NCT00251134	omega-3 fatty acids 1g daily (and standard medical therapy) versus standard medical therapy alone	Patients within 3-14 days after a non-ST-elevation myocardial infarction (NSTEMI) or ST-elevation myocardial infarction (STEMI)	open Follow-up duration: 1 year Germany
phenprocoumon versus aspirin
German-Austrian Study Group (oac vs asp), 1980	phenprocoumon versus aspirin 1.5 g daily	patients who had survived a myocardial infarction for 30-42 days	double blind Follow-up duration: 2 years
phenprocoumon versus placebo
German-Austrian Study Group (oac vs pbo), 1980	phenprocoumon versus placebo	patients who had survived a myocardial infarction for 30-42 days	double blind Follow-up duration: 2 years
pravastatin versus placebo
CARE, 1996	pravastatin 40 mg/d versus placebo	men and women with myocardial infarction who had plasma totalcholesterol levels below 240 mg per deciliter (mean,209) and low-density lipoprotein (LDL) cholesterollevels of 115 to 174 mg per deciliter	double blind Follow-up duration: 5 years USA, Canada
LIPID, 1998	pravastatin 40 mg/d versus placebo	patients with previous myocardial infarction or unstable angina and a baseline plasma cholesterol concentration of 4.0-7.0 mmol/L	double blind Follow-up duration: 6.1 years Australie et Nouvelle Zélande
PACT, 2004	pravastatin initiated within 24 hours of onset of synmptoms and for 4 weeks versus placebo	patients with unstable angina, non-ST-segment elevation myocardial infarction, or ST-segment elevation myocardial infarction <24 hours	double blind Follow-up duration: 30 days
simvastatin versus placebo
4S, 1994	simvastatin 20 or 40 mg/d, target CT between 3 et 5.2 mmol/l versus placebo	patients with angina pectoris or previous myocardial infarction and serum cholesterol 5.5-8.0 mmol/L on a lipid-lowering diet	double blind Follow-up duration: 5.4 years Scandinavia
succinobucol versus placebo
ARISE, 2007 NCT00066898	succinobucol (300 mg/day) versus placebo	high-risk patients with recent acute coronary syndrome	Double blind Follow-up duration: 24 months mean canada, US, UK, South Africa
ticagrelor versus placebo (on top aspirin)
PEGASUS 60mg, 2015 NCT01225562	ticagrelor at a dose of 60 mg twice daily versus placebo	patients who had had a myocardial infarction 1 to 3 years earlier	double-blind Follow-up duration: 2.75 y (median)
PEGASUS 90mg, 2015 NCT01225562	ticagrelor at a dose of 90 mg twice daily versus	patients who had had a myocardial infarction 1 to 3 years earlier	double-blind Follow-up duration: 2.75 y (median)
verapamil versus placebo
DAVIT I, 1984	verapamil 120mgx3 versus placebo		Double blind Follow-up duration: 6 months Danish
DAVIT II, 1990	verapamil 120mgx3 for 18 months versus placebo	patients <76years with diagnosis of acute MI	Double blind Follow-up duration: 16 months Danish
CRIS, 1996	verapamil retard 360 mg daily versus placebo	patients admitted for acute myocardial infarction	Double blind Follow-up duration: 23.5 months Italy
Danish study, 1984	verapamil 0.1mg/kg IV plus 3x120mg orally versus placebo	patients under 75 years of age admitted to the CCU with a suspicion of acute myocardial infarction	double blind Follow-up duration: 12 months Danish
vorapaxar versus placebo (on top aspirin)
TRA-2P TIMI 50, 2012 NCT00526474	vorapaxar (SCH 530348) 2.5-mg daily versus placebo (added to the existing standard of care for preventing heart attack and stroke (eg, aspirin, clopidogrel)	patients with a known history of atherosclerosis (MI, ischemic stroke, or peripheral vascular disease)	double-blind Follow-up duration: 2.5 y (median)
warfarin versus aspirin
WARIS II (warfarin alone), 2002	warfarin target INR 2.8-4.2 versus ASA 160mg/d	patients hospitalized for acute myocardial infarction	NA Follow-up duration: 48 months Norway
warfarin versus control (on top of aspirin)
WARIS, 1999	warfarin 2.8–4.8 versus placebo	survivors of acute myocardial infarction	double blind Follow-up duration: 37 months
APRICOT-2, 2002	moderate-intensity coumarin target INR 2-3 (+aspirin) versus aspirin	Acute MI after thrombolytics	open Follow-up duration: 3 months the Netherlands
CARS (warafrin 3mg), 1997	warfarin fixed dose 3mg/d + 80 mg ASA versus aspirin 160 mg/d	AMI	double blind Follow-up duration: 14 months North America
CARS (warfarin 1mg), 1997	warfarin 1mg/d + aspirin 80mg/d versus aspirin 160 mg/d	patients who had had myocardial infarction	double blind Follow-up duration: 14 months North America
CHAMP, 2002	warfarin target INR 1.5-2.5 + aspirin 81 mg daily versus aspirin 162 mg/d	AMI (patients enrolled within 14 days of infarction)	open Follow-up duration: 2.7 years US
LoWASA, 2004	warfarin fixed dose 1.25mg/d + ASA 75mg/d versus aspirin alone	AMI	open Follow-up duration: 5 years Sweden
WARIS II (warfarin+ASA), 2002	warfarin target INR 2-2.5 +ASA 75mg/d versus ASA 160mg/d	patients hospitalized for acute myocardial infarction	open Follow-up duration: 4 years Norway
Zibaeenezhad, 2004	Warfarin target INR 2–3 +aspirin versus aspirin 100 mg/day	Acute MI	open Follow-up duration: 1 year
warfarin versus placebo (on top of aspirin)
Williams, 1997	warfarin target INR 2–2.5 +aspirin versus placebo +aspirin	Acute MI, unstable angina	double blind Follow-up duration: 2.5 months